Cash/Burn From SEC Filing For Period: 

Q3 '19

SELB

Selecta Biosciences

Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR immune tolerance platform. At our core, we are problem-solvers dedicated to transforming the lives of patients and their families who struggle with serious and debilitating diseases.

Cash

$0.30M

Burn Rate

$12.0M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

SEL-212

Tophaceous gout

Phase 2 (COMPARE)

1Q 2020

SEL-313

methylmalonic acidemia

Phase 1

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon